Abstract:The molecular mechanisms involved in the progression of clear cell renal cell carcinomas (ccRCCs) are still unclear. The aim of this study was to analyse the relationships between expression of RALYL and clinical characteristics. In 41 paired samples of ccRCCs and adjacent normal tissues, we used real-time qPCR to evaluate the expression of RALYL mRNA. RALYL protein levels were determined in 146 samples of ccRCC and 37 adjacent normal tissues by immunohistochemistry. Statistical analysis was used to explore the relationships between expression of RALYL and the clinical characteristics (gender, age, tumor size, T stage, N stage, M stage, survival times and survival outcome) in ccRCC. In addition, these patients were follow-up period 64 months (range: 4~116 months) to investigate the influence on prognosis. We found significantly differences between ccRCC tissues and normal tissues (p<0.001, paired-sample t test) in mRNA levels of RALYL. Immunohistochemistry analyses in 146 ccRCC samples and 37 adjacent normal tissues showed significantly lower RALYL protein levels in ccRCC samples (χ2-test, p<0.001), inversely correlating with tumour size (p=0.024), T stage (0.005), N stage (p<0.001) as well as M stage (p=0.019), but not age (p=0.357) and gender (p=0.348). Kaplan-Meier survival analysis demonstrated that people with lower level of RALYL expression had a poorer survival rate than those with a higher level of RALYL expression, significantly different by the log-rank test (p=0.011). Cox regression analysis indicated that RALYL expression (p=0.039), N stage (p=0.008) and distant metastasis (p<0.001) were independent prognosis factors for the overall survival of ccRCC patients. We demonstrated that the expression of RALYL was significantly low in ccRCC and correlated with a poor prognosis in a large number of clinical samples. Our findings showed that RALYL may be a potential therapeutic target as well as a poor prognostic factor.

RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma

LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription.

Hypermethylation-mediated Transcriptional Silencing of Lncrna-Scarf1 Promotes Progression and Metastasis of Hepatocellular Carcinoma

O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export

RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2

RNA binding protein RALY facilitates colorectal cancer metastasis via enhancing exosome biogenesis in m6A dependent manner

RNA-binding Protein RALY Reprogrammes Mitochondrial Metabolism Via Mediating Mirna Processing in Colorectal Cancer

ALYREF Mediates RNA M5c Modification to Promote Hepatocellular Carcinoma Progression

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

STAT5A Modulates CDYL2/SLC7A6 Pathway to Inhibit the Proliferation and Invasion of Hepatocellular Carcinoma by Targeting to Mtorc1

KIAA1429 regulates alternative splicing events of cancer-related genes in hepatocellular carcinoma

The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis

Long non-coding RNA SREBF2-AS1 promotes cell progression by increasing SREBF2 expression in Hepatocellular carcinoma

Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing

RNA‐binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152

HnRNPR-mediated UPF3B Mrna Splicing Drives Hepatocellular Carcinoma Metastasis.

Cleavage and Polyadenylation Specific Factor 1 Promotes Tumor Progression via Alternative Polyadenylation and Splicing in Hepatocellular Carcinoma

PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2

ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells

Splicing Regulator p54nrb/Non–POU Domain–Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box–Dependent Interacting Protein 1 in Hepatocellular Carcinoma

RALY RNA Binding Protein-Like Reduced Expression is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma.